Spots Global Cancer Trial Database for acute myeloid leukemia, adult

Every month we try and update this database with for acute myeloid leukemia, adult cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia	NCT05001828	Acute Myeloid L...	ADI-PEG 20	18 Years - 99 Years	Polaris Group
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation	NCT03951961	Acute Myeloid L...	Midostaurin	18 Years -	University of Jena
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML	NCT05703126	Acute Myeloid L... Cardiotoxicity Endothelial Dys...	History taking Anthropometry Complete blood ... Biochemical blo... Coagulogram Immunoenzymatic... Stress echocard... Triplex scannin... Electrocardiogr... Ultrasound of t... Cytogenetic exa... Cytological exa... Immunophenotypi... Determination o... laser Doppler f...	18 Years - 65 Years	Samara State Medical University
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome	NCT05674539	Acute Myeloid L... Myelodysplastic... Allogeneic Hema...	Fludarabine and... Fludarabine and...	18 Years -	Wuhan Union Hospital, China
Effect of a Hyperproteic Hyperenergetic Enteral Formula on Body Composition and VEGF in AML During Hospital Stay	NCT04240600	Acute Myeloid L...	Experimental gr... Control group	18 Years - 60 Years	Hospital General de Mexico
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML	NCT04050280	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L...	Cladribine, Cyt...	18 Years -	University of Maryland, Baltimore
Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75	NCT03902665	Acute Myeloid L...	Up-front alloge...	65 Years - 75 Years	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients	NCT06252584	Acute Myeloid L...	Vaccines, Pepti...	18 Years -	University Hospital Tuebingen
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.	NCT05127798	Acute Myeloid L...	Evaluation of f...	18 Years - 70 Years	Grupo Argentino de Tratamiento de la Leucemia Aguda
First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients	NCT05601726	Acute Myeloid L... Myelodysplastic...	ABD-3001 ABD-3001	18 Years -	Advanced BioDesign
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features	NCT04752527	Acute Myeloid L...	venetoclax comb...	18 Years - 59 Years	The First Affiliated Hospital of Soochow University
Lentivirally Redirected CD123 Autologous T Cells in AML	NCT03766126	Acute Myeloid L... Acute Myeloid L... Acute Myeloid L...	CART123 cells; ...	18 Years -	University of Pennsylvania
Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia	NCT05988047	Acute Myeloid L...		18 Years - 99 Years	University of Freiburg
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome	NCT05674539	Acute Myeloid L... Myelodysplastic... Allogeneic Hema...	Fludarabine and... Fludarabine and...	18 Years -	Wuhan Union Hospital, China
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features	NCT04752527	Acute Myeloid L...	venetoclax comb...	18 Years - 59 Years	The First Affiliated Hospital of Soochow University
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease	NCT06200441	Acute Myeloid L... Graft Versus Ho... Endothelial Dys...		18 Years -	Ankara University
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia	NCT05001828	Acute Myeloid L...	ADI-PEG 20	18 Years - 99 Years	Polaris Group
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome	NCT05674539	Acute Myeloid L... Myelodysplastic... Allogeneic Hema...	Fludarabine and... Fludarabine and...	18 Years -	Wuhan Union Hospital, China
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation	NCT03951961	Acute Myeloid L...	Midostaurin	18 Years -	University of Jena
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.	NCT05127798	Acute Myeloid L...	Evaluation of f...	18 Years - 70 Years	Grupo Argentino de Tratamiento de la Leucemia Aguda
Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia	NCT02985372	Acute Myeloid L...	Decitabine Cytarabine	60 Years - 75 Years	Shandong University
Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy	NCT04454580	Acute Myeloid L... Hypomethylating... Venetoclax	Venetoclax	18 Years -	Ospedale Maggiore Di Trieste
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML	NCT05133882	Acute Myeloid L...	Clifutinib Besy...	18 Years -	Sunshine Lake Pharma Co., Ltd.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: